Symptoms after taking tofacitinib/Shangjie for 6 years

Tofacitinib/Shangjie (Tofacitinib) is an immunomodulatory drug that can be used for a long time. What patients are most concerned about during long-term treatment is often not the short-term response, but "what changes will occur in the body after years of use." According to global long-term follow-up studies and real-world data, patients who take tofacitinib for more than 6 years usually show a pattern of "stable disease and controlled symptoms, but require continuous monitoring of immune and metabolic indicators."

Part of the value of tofacitinib is in providing long-term control in chronic immune diseases such as rheumatoid arthritis, psoriatic arthritis and ankylosing spondylitis. Many patients maintain symptoms such as joint pain, stiffness, and skin inflammation at stable levels after years of treatment, and some patients can reduce the frequency of acute attacks. For people with ulcerative colitis, the goal of long-term use is to maintain the stable state of the intestinal mucosa and reduce symptoms such as recurrent diarrhea and abdominal pain, thereby improving the quality of life.

During long-term use, some manifestations of concern are mainly related to immune regulatory mechanisms. Some patients may experience mild changes in blood lipids during many years of treatment, so overseas guidelines recommend regular monitoring of blood lipids during long-term follow-up and cooperation with lipid-lowering treatment when necessary. At the same time, since tofacitinib inhibits some inflammatory pathways, long-term patients need to pay attention to the risk of infection, especially during seasonal changes or temporary decline in immunity. As global research on the safety of JAK inhibitors increases, long-term factors such as cardiovascular risk and thrombotic risk are also included in the scope of monitoring. Therefore, patients who use them for more than 6 years usually receive regular follow-up to ensure safety.

It is worth noting that many patients report improved drug compliance and more stable daily symptom control after years of use. This is related to the convenience of oral administration of tofacitinib, which makes it have better continuous treatment properties in the management of chronic diseases.

Reference materials: https://www.xeljanz.com/